SS

Sujatha Sekhar Gadiraju

Active Director Director DIN 10056724
DIN 10056724 First appointment Mar 2023 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Sujatha Sekhar Gadiraju

Data last updated:

Sujatha Sekhar Gadiraju is a Director at Verk Pharmaceuticals Private Limited (since 2023). The company operates in Pharma.

DIN 10056724
Primary Designation Director
Industry Pharma
First Appointment 15 Mar 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Verk Pharmaceuticals Private Limited U47721TN2023PTC158881
Director15 Mar 20232023Active

Board colleagues of Sujatha Sekhar Gadiraju

NameDINCompanyDesignation
Nishita Sekhar Gadiraju10056725Verk Pharmaceuticals Private LimitedDirector

Directorship timeline

Open interactive timeline →
Verk Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sujatha Sekhar Gadiraju

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sujatha Sekhar Gadiraju

Sujatha Sekhar Gadiraju currently holds 1 directorship: Verk Pharmaceuticals Private Limited (Director, since 15 Mar 2023).

Sujatha Sekhar Gadiraju was first appointed on 15 Mar 2023 as Director at Verk Pharmaceuticals Private Limited.

The current boards of Sujatha Sekhar Gadiraju's companies include Nishita Sekhar Gadiraju (Verk Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available